Due to health issues, this site is no longer maintained and will be shut down shortly.

PLRX Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapeutics that seek to halt progression of fibrotic diseases ultimately preserving organ function. Our lead product candidate, PLN-74809, is an orally available small molecule designed to be a selective inhibitor of av1 and av6, two integrins that play key roles in multiple fibrotic pathways. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). We are currently conducting Phase 2a trials of PLN-74809 for the treatment of IPF and plan to initiate a Phase 2a trial in PSC in the second half of 2020. Pliants second clinical stage product candidate, PLN-1474, is designed to be a small molecule selective inhibitor of av1, targeting liver fibrosis associated with nonalcoholic steatohepatitis (NASH) and is partnered with Novartis. PLN-1474 is currently in Phase 1 testing. In addition to our clinical stage programs, we currently have preclinical programs targeting oncology and muscular dystrophies.

$26.57  +0.97 (3.79%)
As of 03/27/2023 14:17:34 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/03/2020
Outstanding shares:  58,939,667
Average volume:  403,119
Market cap:   $1,535,378,325
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMDWW66
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy